Research Article

[Retracted] LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients

Figure 4

Immune targets of CD8+ T cell responses to treatment for DLBCL patients. (a) Purity of sorted CD8+ T cells from DLBCL patients. (b) Cytokine production levels in the cells of each group. , , and compared with treatment group. DLBCL: diffuse large B-cell lymphoma; PD1: programmed cell death protein 1; LAG3: lymphocyte activation gene 3.
(a)
(b)